StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Analysts at StockNews.com assumed coverage on shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) in a research note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

Brainstorm Cell Therapeutics Price Performance

NASDAQ BCLI opened at $1.65 on Monday. The business has a 50 day simple moving average of $1.91 and a 200 day simple moving average of $2.32. Brainstorm Cell Therapeutics has a one year low of $1.05 and a one year high of $11.89. The stock has a market capitalization of $9.41 million, a P/E ratio of -0.34 and a beta of 0.74.

About Brainstorm Cell Therapeutics

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.